pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

avillion PRESS RELEASE ARCHIVE

May 31, 2022

US FDA accepts New Drug Application filed by Avillion for AstraZeneca's PT027 for the as-needed treatment or prevention of symptoms in asthma patients

May 15, 2022

Avillion announces publication of positive full results from MANDALA Phase III trial of AstraZeneca's PT027 in asthma patients in the New England Journal of Medicine

Sep 9, 2021

Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca's PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients

Apr 23, 2021

Avillion's positive Phase 2 trial of tri-specific Nanobody sonelokimab (M1095) in chronic psoriasis published in The Lancet

Oct 29, 2020

Positive results from Avillion's Phase 2 trial of sonelokinab (M1095) in chronic psoriasis to be presented today in Late-Breaking News Session at EADV 2020 Virtual

Sep 10, 2020

Avillion announces positive top-line results of Phase 2 trial of sonelokinab (M1095), an anti-IL-17 A/F Nanobody, in chronic psoriasis

Sep 5, 2019

Avillion Appoints Dr Anders Gersel Pedersen, M.D., Ph.D. as Board Member

Mar 14, 2019

Avillion Appoints Dr David Chiswell OBE as Board Member

Mar 13, 2018

Avillion Signs Co-Development Agreement with Pearl Therapeutics Inc. (part of AstraZeneca) to Conduct Clinical Development of PT027 in Asthma

Feb 16, 2018

Avillion Advances Co-development Programme with Merck: IND Now Open for Phase 2 Study of M1095, an Anti-IL-17 A/F Nanobody in Psoriasis

Dec 19, 2017

Avillion Announces US Approval of Pfizer's BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

Mar 30, 2017

Avillion Signs Clinical Co-development Agreement With Merck to Advance Anti IL-17 A/F Nanobody in Psoriasis

Mar 30, 2017

Merck KGaA, Darmstadt, Germany Advances RandD Strategy through Unique Development Model with Avillion for Anti IL-17 A/F Nanobody

Jan 20, 2017

Avillion Strengthens Clinical and Regulatory Development Capabilities with the Appointment of Mark Weinberg as Chief Medical Officer

Dec 5, 2016

Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Sep 15, 2015

Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

Sep 23, 2014

Avillion Appoints Jarrod Longcor as Chief Business Officer

Feb 18, 2014

Avillion Appoints Dr Allison Jeynes-Ellis as Chief Executive Officer

Jan 9, 2014

Avillion Group Partners with Pfizer to Co-develop BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

May 28, 2013

Avillion Expands Leadership Team with Appointment of Ramani Varanasi as Chief Business Officer

Jan 28, 2013

Avillion LLP Receives Initial Funding From Abingworth and Clarus

Google Analytics Alternative